Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Chronic Myeloproliferative Disorders
Vanderbilt-Ingram Cancer CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
80 Active assets in the Chronic Myeloproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Center for International Blood and Marrow Transplant Research | Phase 2/3 | BBB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2/3 | BB |
Busulphan Sawa Ito, MD | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →